Literature DB >> 14717665

Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast.

K-B Tan1, W-P Yong, T C Putti.   

Abstract

AIMS: To study cyclooxygenase-2 (COX-2) expression in ductal carcinoma in situ (DCIS) of the breast and its association with histological features. COX-2, an inducible prostaglandin synthase, has been shown to be important in mammary carcinogenesis, being associated with increased tumour size and unfavourable outcome in breast cancer. Animal studies indicate that COX-2 inhibition is effective in the prevention and treatment of mammary cancers. METHODS AND
RESULTS: Fifty-one cases of DCIS diagnosed during 1990-2000 were reviewed. Immunohistochemistry for COX-2 was performed and the COX-2 staining scores were correlated with histological features. The majority of cases [41 of 51 (80%)] had positive COX-2 staining, of which 13 cases (25%) had strong staining. High nuclear grade DCIS was significantly associated with increased COX-2 staining (P = 0.04).
CONCLUSIONS: High-grade lesions are known to be associated with a higher recurrence rate following excision and are often oestrogen receptor negative, and as such, may be less responsive to adjuvant tamoxifen therapy. There is a need to examine further the role of COX-2 expression in DCIS, as both a prognostic and predictive factor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14717665     DOI: 10.1111/j.1365-2559.2004.01774.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  14 in total

1.  The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast.

Authors:  Nagehan Ozdemir Barısık; Sevinc Hallac Keser; Aylin Ege Gul; Sibel Sensu; Nilufer Onak Kandemir; Hasan Fehmi Kucuk; Mahmut Gumus; Nimet Karadayı
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

2.  Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment.

Authors:  Giuliana Cássia Morrone Taromaru; Vilmar Marques DE Oliveira; Maria Antonieta Longo Galvão Silva; Wagner Ricardo Montor; Fabio Bagnoli; José Francisco Rinaldi; Tsutomu Aoki
Journal:  Oncol Lett       Date:  2011-12-21       Impact factor: 2.967

3.  Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.

Authors:  Katrine L Henriksen; Birgitte B Rasmussen; Anne E Lykkesfeldt; Susann Møller; Bent Ejlertsen; Henning T Mouridsen
Journal:  J Clin Pathol       Date:  2006-06-14       Impact factor: 3.411

4.  Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum.

Authors:  Pratima Nangia-Makker; Larry Tait; Malathy P V Shekhar; Eduardo Palomino; Victor Hogan; Marie P Piechocki; Tatsuyoshi Funasaka; Avraham Raz
Journal:  Int J Cancer       Date:  2007-08-15       Impact factor: 7.396

5.  Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Authors:  Kathrin Strasser-Weippl; Michaela J Higgins; Judith-Anne W Chapman; James N Ingle; George W Sledge; George T Budd; Matthew J Ellis; Kathleen I Pritchard; Mark J Clemons; Tanja Badovinac-Crnjevic; Lei Han; Karen A Gelmon; Manuela Rabaglio; Catherine Elliott; Lois E Shepherd; Paul E Goss
Journal:  J Natl Cancer Inst       Date:  2018-09-01       Impact factor: 13.506

6.  Urinary prostaglandin E2 metabolite and breast cancer risk.

Authors:  Yong Cui; Xiao-Ou Shu; Yu-Tang Gao; Qiuyin Cai; Bu-Tian Ji; Hong-Lan Li; Nathaniel Rothman; Jie Wu; Gong Yang; Yong-Bing Xiang; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-09-11       Impact factor: 4.254

Review 7.  Cyclooxygenase-2 and the inflammogenesis of breast cancer.

Authors:  Randall E Harris; Bruce C Casto; Zachary M Harris
Journal:  World J Clin Oncol       Date:  2014-10-10

8.  Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.

Authors:  Sara A Lari; Henry M Kuerer
Journal:  J Cancer       Date:  2011-05-01       Impact factor: 4.207

9.  Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells.

Authors:  Rania Harati; Aloïse Mabondzo; Abdelaziz Tlili; Ghalia Khoder; Mona Mahfood; Rifat Hamoudi
Journal:  Breast Cancer Res Treat       Date:  2021-05-26       Impact factor: 4.872

Review 10.  Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.

Authors:  Louise R Howe
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.